We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+42.02%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$301M
AUM Growth
+$81.5M
Cap. Flow
+$21.5M
Cap. Flow %
7.15%
Top 10 Hldgs %
57.04%
Holding
59
New
3
Increased
11
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$11M
2
EXEL icon
Exelixis
EXEL
+$8.09M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$6.53M
4
GILD icon
Gilead Sciences
GILD
+$5.06M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$4.17M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$6.4M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.52M
3
AMGN icon
Amgen
AMGN
+$3.19M
4
LLY icon
Eli Lilly
LLY
+$2.77M
5
INCY icon
Incyte
INCY
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
51
DELISTED
Esperion Therapeutics
ESPR
$452K 0.15%
9,500
– –
ANAB icon
52
AnaptysBio
ANAB
$1.7B
$227K 0.08%
10,000
– –
ZEAL
53
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$187K 0.06%
5,653
– –
ALKS icon
54
Alkermes
ALKS
$8.2B
– –
-52,000
Closed -$749K
AMRN
55
Amarin Corp
AMRN
$297M
– –
-16,000
Closed -$1.27M
LLY icon
56
Eli Lilly
LLY
$1.05T
– –
-20,000
Closed -$2.77M
MRK icon
57
Merck
MRK
$369B
– –
-87,194
Closed -$6.4M
TPST icon
58
Tempest Therapeutics
TPST
$17.9M
– –
-912
Closed -$939K
TCDA
59
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-29,000
Closed -$635K
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2020 Portfolio in Review

As of Q2 2020, International Biotechnology Trust held 59 positions worth $301M, up 37% from $219M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust deployed $21.5M of net new capital in Q2 2020, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 11,500 shares worth $7.02M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $3.52M trimmed.

  • International Biotechnology Trust's largest Q2 2020 buy was Regeneron Pharmaceuticals: 11,500 shares worth $7.02M.
  • International Biotechnology Trust added most to Immunomedics Inc in Q2 2020, an estimated $11M increase.
  • International Biotechnology Trust's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $3.52M.
  • International Biotechnology Trust fully exited Merck in Q2 2020, selling an estimated $6.4M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $301M portfolio in Q2 2020.
  • International Biotechnology Trust opened 3 new positions and closed 6 in Q2 2020.
  • International Biotechnology Trust's portfolio value rose 37% quarter-over-quarter to $301M.

Based on International Biotechnology Trust's 13F filing for Q2 2020, filed 14 Jul 2020.